Previous studies showed that peroxisome proliferator-activated receptor (PPAR)-γ, insulin sensitizers, reduced recurrent stroke to 66% (95% CI = 44–99%) in patients with stroke or transient ischemic attack compared to the placebo in a meta-analysis of three randomized clinical trials (RCT) [6]. This evidence concerns the gene PPARG and stroke disorder.